- Investing.com
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company’s NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company’s platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Metrics to compare | BBLG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBBLGPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.6x | −1.6x | −0.6x | |
PEG Ratio | −0.01 | 0.04 | 0.00 | |
Price / Book | 1.0x | −0.1x | 2.6x | |
Price / LTM Sales | - | 0.1x | 3.2x | |
Upside (Analyst Target) | - | 301.3% | 48.5% | |
Fair Value Upside | Unlock | 12.3% | 7.8% | Unlock |